Biblio
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. Cell Host Microbe. 2024.
Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases. J Autoimmun. 2023;136:103024.
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2024:JCO2301159.
. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID. EBioMedicine. 2023;94:104700.
Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Reporting infectious complications in haematology clinical trials should be improved. Clin Microbiol Infect. 2019.
. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.
Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol. 2024:JCO2400032.
Varicella zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis - the incidence remains high. Biol Blood Marrow Transplant. 2014.
.